Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials

Journal of the National Cancer Institute

Volumn 89, Issue 21, 1997, Pages 1616-1620

  Delannoy, A ^a   Kluin Nelemans, J C ^a   Louwagie, A ^a   Stryckmanns, P ^a   Suciu, S ^a   Hehlmann, R ^a   Heimpel, H ^a   Hasford, J ^a   Zuffa, E ^a   Baccarani, M ^a   Tura, S ^a   Ohnishi, K ^a   Ohno, R ^a   Allan, N ^a   Shepherd, P ^a   Broustet, A ^a   Alison, R ^a   Clarke, M ^a   Duong, H ^a   Gray, R ^a   Greaves, E ^a   Peto, R ^a   Richards, S ^a   Sinclair, D ^a   Wheatley, K ^a   more..

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; META ANALYSIS; OUTCOMES RESEARCH; PHILADELPHIA 1 CHROMOSOME; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0030715606     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.21.1616     Document Type: Article

References (14)

1. Gordon MY, Goldman JM. Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br J Haematol 1996;95:10-20.
2. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994;330:820-5.
3. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfield DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994;84:4064-77.
4. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alfa n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia. Lancet 1995;345:1392-7.
5. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86: 906-16.
6. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med 1995;14:2057-79.
7. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339: 1-15.
8. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J 1988;296:320-31.
9. Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia. The Benelux CML Study Group. Bone Marrow Transplant 1996;17(Suppl 3):s19-s20.
10. Broustet A, Reiffers J, Marit G, Fiere D, Jaubert J, Reynaud J, et al. Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study. Eur J Cancer 1991;27(Suppl 4):s18-s21.
11. Jacobson RJ, St. Germain D. Reduced toxicities using interferon-alfa (IFN) and hydroxyurea in chronic myelogenous leukemia (CML). ECCO meeting abstracts 1991;6:s254.
12. Moro MJ, Gil S, Canizo C, Clemente J Fernandez, Guerras L, Fisac RM, et al. The treatment of chronic myelogenous leukemia with interferon alfa-2b plus hydroxyurea versus hydroxyurea alone. Haematologica 1991;76(Suppl 4):117.
13. Sokal JE, Cox EB, Baccarani MI, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
14. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfield DK, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82:398-407.